[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Vaccine Dealmaking in Biopharma Investigated in New CurrentPartnering Study Now Available at MarketPublishers.com

09 Jan 2014 • by Natalie Aster

LONDON – What are the prevailing trends in vaccine dealmaking in the overall biopharma industry since 2007? What is actually granted by the vaccine dealmaking agreement to a partner company? What are the precise rights optioned or granted? What does the payment structure of the deal look like? How are payments and sales audited? How are the main terms of the vaccine partnering agreement defined? Which of the partner companies is responsible for commercialisation, development, manufacture and supply? How is publication and confidentiality managed? How are different disputes resolved? What influence does the change of ownership have on dealmaking? What subcontracting and sublicensing provisions have been agreed upon during dealmaking? Which boilerplate clauses differ from deal type to deal type or partner to partner? Which jurisdiction does the company insist upon for agreement law?

All these questions and many more burning issues are thoroughly discussed in the new research study “Vaccine Partnering Terms and Agreements” worked out by CurrentPartnering.

The report offers a profound understanding and a comprehensive analysis of how and why various companies enter vaccine partnering deals. The research study presents an insightful overview of the leading vaccine deals since 2007, sheds light on the major trends in vaccine partnering deals, provides an in-depth analysis of deal terms, covers the partnering agreement structure in detail. It also grants access to more than 1,100 vaccine deal documents; the available vaccine deal contracts are listed by headline value, specific technology type, stage of development at signing, company A-Z, deal component type and therapy target. It uncovers vaccine agreement deals ranking by value and discloses important information on the most active dealmakers. The report answers numerous questions about prospective partner’s flexibility on a wide spectrum of significant issues, many of which will likely have a considerable influence on each party’s ability to gain benefits from a deal.

Report Details:

Vaccine Partnering Terms and Agreements
Published: January, 2014
Pages: 1508
Price: US$ 2,995.00 

Other Reports on Healthcare Partnering Terms & Agreements by CurrentPartnering Include:

More studies by the publisher can be found at CurrentPartnering page.


The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 

Analytics & News

Weekly Digest